關(guān)鍵詞

DNA甲基化 內(nèi)質(zhì)網(wǎng) 免疫治療 原聚體 阿爾茨海默病?APOE?ADC藥物 那他珠單抗 恩沃利單抗 利生奇珠單抗

?

#今日行業(yè)熱點#

①Cell：Chromatin remodeling of histone H3 variants by DDM1 underlies epigenetic inheritance of DNA methylation

DDM1引起的組蛋白H3變異體的染色質(zhì)重塑是DNA甲基化表觀遺傳的基礎(chǔ)

DOI: 10.1016/j.cell.2023.08.001

②Cell：PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development

PINK1、Keap1和Rtnl1調(diào)節(jié)發(fā)育過程中內(nèi)質(zhì)網(wǎng)的選擇性清除

DOI: 10.1016/j.cell.2023.08.008

③Cancer Cell：KRASG12D?inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+?T cells

抑制KRASG12D可重編程早期和晚期胰腺癌(PDAC)的微環(huán)境，促進(jìn)FAS介導(dǎo)的CD8+ T細(xì)胞殺傷

DOI: 10.1016/j.ccell.2023.07.002

④Cancer Cell：Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy

腫瘤免疫原性決定了CD8+ T細(xì)胞對免疫治療的應(yīng)答依賴于T細(xì)胞因子1 (TCF1)

DOI: 10.1016/j.ccell.2023.08.001

⑤Cell Chemical Biology：Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex

RAS/RAF復(fù)合物中II型RAF抑制劑的原聚體選擇性

DOI: 10.1016/j.chembiol.2023.07.019

⑥Cell Reports：Cell-type-specific regulation of APOE and CLU levels in human neurons by the Alzheimer’s disease risk gene SORL1

阿爾茨海默病風(fēng)險基因SORL1對人類神經(jīng)元中載脂蛋白E (APOE)和叢生蛋白(CLU)水平的細(xì)胞類型特異性調(diào)節(jié)

DOI: 10.1016/j.celrep.2023.112994

⑦實驗室設(shè)備和其他用品制造商丹納赫（Danaher）以57億美元收購英國蛋白質(zhì)耗材制造商Abcam

⑧首個那他珠單抗生物類似藥Tyruko獲FDA批準(zhǔn)上市，用于多發(fā)性硬化癥（MS）和克羅恩?。–D）

⑨PD-L1抑制劑恩沃利單抗獲國家藥監(jiān)局批準(zhǔn)開展用于非小細(xì)胞肺癌患者的III期臨床研究

⑩白細(xì)胞介素-23（IL-23）抑制劑利生奇珠單抗用于中度至重度活動性潰瘍性結(jié)腸炎成人患者的新適應(yīng)癥已向FDA和EMA遞交上市申請

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！